Sign In
Buy NXL
$0.533
-0.0175 (-3.18%)
At Close: Jun 03, 2026
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9
09:00am, Monday, 25'th Aug 2025
HOUSTON, TX, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on September 9, 2025, at 4
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of th
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3
10:00am, Wednesday, 28'th May 2025
HOUSTON, TX, May 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar on June 3, 2025, at 4:15 p.
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data
08:30am, Tuesday, 13'th May 2025
HOUSTON, TX, May 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
02:40pm, Tuesday, 06'th May 2025
HOUSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the b
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
08:20am, Monday, 05'th May 2025
HOUSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the br
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
10:30am, Thursday, 01'st May 2025
Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia, and MCI indications Company initiates formal regulatory engagement on trial design for Alzheimer's, dementia,
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
09:00am, Thursday, 24'th Apr 2025
HOUSTON, TX, April 24, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of th
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monit
HOUSTON, TX, April 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of th
Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addiction Treatment Patent Approval Reinforces Nexalin's Leadership in Non-Invasive Brain Stimulation for Addictio
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
08:30am, Wednesday, 02'nd Apr 2025
HOUSTON, TX, April 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of th
Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3
08:30am, Wednesday, 26'th Mar 2025
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15
Patent Strengthens Nexalin's Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and Methamphe
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval
08:30am, Friday, 28'th Feb 2025
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials
